Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06273852 · ClinicalTrials.gov registry record · Early Phase 1
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
A Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer, sponsored by Pure Biologics S.A..
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
- 4
- Study locations
NCT06273852 is a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer that has completed, run by Pure Biologics S.A.. The registered enrollment target is 8 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06273852, a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer, has completed, sponsored by Pure Biologics S.A..
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.
Conditions Studied
Interventions
- DRUG PBA-0405
Study Locations (4)
Louisiana
- LSU Health Sciences Center - Shreveport
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
South Carolina
- Sarah Cannon Research Institute - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2025-03-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06273852
The ClinicalTrials.gov registry entry for NCT06273852 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is Pure Biologics S.A., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which PBA-0405 is the first listed.
NCT06273852 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Louisiana, Oregon, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06273852 about?
NCT06273852 is a clinical study titled "A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors". This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.
What is the current status of trial NCT06273852?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2024-04-29. Estimated completion is 2025-03-31.
What conditions does trial NCT06273852 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Soft Tissue Sarcoma Adult.
What interventions are being tested in trial NCT06273852?
The interventions under investigation include: PBA-0405 (DRUG).
Who is sponsoring clinical trial NCT06273852?
This trial is sponsored by Pure Biologics S.A., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06273852 being conducted?
This trial has 4 study locations across Louisiana, Oregon, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RECRUITING · Early Phase 1
-
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
RECRUITING · Early Phase 1
-
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
RECRUITING · Early Phase 1
-
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
RECRUITING · Early Phase 1
-
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
RECRUITING · Early Phase 1
-
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
RECRUITING · Early Phase 1
Explore more on PlainTrial
Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Triple Negative Breast Cancer
All registered trials for this condition
Louisiana
All trials with a study site in Louisiana
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.